Neautus looks outward to boost its traditional medicine story
The maker of traditional Chinese medicines has applied for a Hong Kong IPO after abandoning two listing attempts on China’s domestic A-share market Key Takeaways: Neautus has applied to list…
Joinn Labs undermined by AI as FDA phases out animal drug testing
The outsourced clinical research services provider’s shares tumbled after the U.S. drug regulator announced a new approach to drug testing Key Takeaways: Joinn Labs’ shares fell on heavy trading as…
Investors cheer Akeso’s revenue milestone, even as it returns to the red
The drugmaker’s shares rallied after the release of its strong annual report, up by a cumulative 18% over the next three trading days Key Takeaways: Akeso’s drug sales rose 25%…
Dispute over Covid vaccines casts doubt on Clover Bio recovery
The Chinese biopharma firm faces a potentially damaging fight over a $224 million upfront payment it received in an ill-fated deal to supply Covid vaccines Key Takeaways: The Gavi international…
CARsgen seeks cell therapy breakthrough but stays in the red for now
The developer of specialized cancer treatments is shifting from costly personalized therapy to more standardized options, but at the price of short-term financial pain Key Takeaways: The company launched its…
Everest Medicines drives growth with AI-powered mRNA pipeline
The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine’s EVM14 cancer vaccine…
A blockbuster cancer drug? TYK’s claims go under the microscope
The medicines company released scanty but promising results for an experimental drug just as its shares were joining the Hong Kong Stock Connect scheme Key Takeaways: The drug being developed…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Innogen Pharma jostles for a slice of the weight-loss market
-
CATL leads new charge of Mainland-listed companies into Hong Kong
300750.SHE
-
Baozun returns to the black as Gap expansion accelerates
9991.HK BZUN.US
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
